FDA Issues Draft Guidance Prioritizing Overall Survival as Primary Endpoint for Cancer Drug Approvals
核心洞察
The FDA has published new draft guidance emphasizing overall survival (搜索) as the preferred primary endpoint for cancer (搜索) drug trials, marking a shift toward prioritizing long-term patient outcomes in the approval process.
The guidance comes less than two weeks after the return of CBER Head Vinay Prasad, who has previously advocated for prioritizing overall survival (搜索) over surrogate endpoints in oncology drug evaluations.
While the new requirements may make accelerated approval more challenging, the FDA still permits this pathway for drugs with significant uncertainty in OS findings but sufficient evidence of efficacy via intermediate clinical endpoints.
The FDA has issued new draft guidance urging pharmaceutical companies to prioritize overall survival (搜索) (OS) as the primary endpoint in clinical trials for cancer (搜索) drugs, a move that could make it more challenging for companies to seek accelerated approval while raising the bar for demonstrating therapeutic benefit.
The draft guidance, published on Tuesday, comes less than two weeks after the unexpected return of Center for Biologics Evaluation and Research (搜索) Head Vinay Prasad, who has previously argued for prioritizing overall survival (搜索) outcomes in oncology drug evaluations.
Emphasis on Gold Standard Endpoint
The draft aims to guide drug sponsors on the use of survival data in their cancer (搜索) drug applications, "with an emphasis on the analysis of overall survival (搜索) as a pre-specified safety endpoint." When feasible, drug developers should prioritize using OS as the primary endpoint in their studies, according to the document.
"Overall survival (搜索) is both an efficacy and a safety endpoint; it can be favorably impacted by the therapeutic benefits of a specific drug and negatively impacted by the drug's toxicity," the FDA wrote, noting that OS is the gold standard outcome in oncology. "Overall survival is also an objective, clinically meaningful endpoint that can be measured easily and precisely."
In cases where using OS as the primary efficacy outcome is not feasible—such as in cancers that progress very slowly or where treatments exist that are very effective and result in long survival times—companies should still collect OS data and submit them to the regulator.
Study Design Recommendations
To avoid confounding OS analysis, the FDA also recommends to "limit" the use of cross-over study designs, permitting these only in diseases with no or very limited therapeutic options.
The guidance aligns with perspectives previously advocated by Prasad, who argued in a paper published in March in Nature Reviews Clinical Oncology that using surrogate endpoints for approval trades speed for therapeutic uncertainties for patients. "If the FDA and other regulators were to shift their priority to patient-centered outcomes, such as OS, I argue that such a shift would probably lead to fewer, but also a higher standard of drugs entering the market," he wrote.
Accelerated Approval Pathway Remains
Despite the stricter requirements, the draft document dedicates a section to accelerated approval, which it says will be appropriate to use for drugs with "significant uncertainty" in OS findings but which have enough evidence to support efficacy via an intermediate clinical endpoint, such as treatment response or progression-free survival.
"The heightened emphasis on OS - particularly in the context of analyzing safety of a novel drug/regimen - is not surprising, given the current FDA leadership," analysts at Truist Securities (搜索) wrote in a note to investors on Tuesday. The firm is also "encouraged" by the fact that accelerated approval still seems to be a possibility for companies despite the "stricter requirements" for OS in confirmatory follow-up.
Outstanding Questions
Some key unanswered questions still remain, according to Truist. "We note that this draft guidance does not address accelerated approvals on the basis of single arm studies," a practice that has grown increasingly common in recent years.
FDA guidelines are legally nonbinding and legally unenforceable—even when finalized. Companies are allowed to take an alternative approach to these recommendations, for which they should contact the agency.